Clinical Evaluation and Identification of Human Coronavirus Infections in Children with Acute Respiratory Infections in Xiamen, China, 2022–2024 - Top-Institutions - MDSpire

Clinical Evaluation and Identification of Human Coronavirus Infections in Children with Acute Respiratory Infections in Xiamen, China, 2022–2024

  • By

  • Xiu-Ping Liu

  • Hao Chen

  • Li Yao

  • Wei Su

  • February 9, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Children's Hospital of Philadelphia
    Children's Hospital of Philadelphia

    Philadelphia, PA

    Key Differentiators

    • Pediatric Infectious Diseases
    • Virology
    • Epidemiology

  • #2

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Virology
    • Immunology

  • #3

    Shanghai Children's Medical Center
    Shanghai Children's Medical Center

    Shanghai, China

    Key Differentiators

    • Pediatric Infectious Diseases
    • Clinical Virology

  • #4

    University of Washington, Seattle Children's Hospital
    University of Washington, Seattle Children's Hospital

    Seattle, WA

    Key Differentiators

    • Pediatric Infectious Diseases
    • Virology

  • #5

    Xiamen Children’s Hospital
    Xiamen Children’s Hospital

    Xiamen, Fujian

    Key Differentiators

    • Pediatric Infectious Diseases
    • Clinical Epidemiology

Original Source(s)

Clinical Evaluation and Identification of Human Coronavirus Infections in Children with Acute Respiratory Infections in Xiamen, China, 2022–2024

  • by Xiu-Ping Liu, Hao Chen, Li Yao, Wei Su

  • February 9, 2026

Related Content

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Primary Care Telemedicine as an Antibiotic Stewardship and Environmental Solution

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.